What did the FDA approve this week for HER2-positive breast cancer — and what did the trial actually show?

The tucatinib maintenance regimen delayed cancer progression in HER2CLIMB-05; overall-survival data remain immature and liver toxicity requires monitoring.

On Oct. 7, the FDA approved tucatinib (Tukysa) with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer. “Maintenance” means continuing treatment after the initial phase to hold the cancer in check.

In the randomized 654-patient HER2CLIMB-05 trial, median progression-free survival—the midpoint for time lived without the cancer worsening—was 24.9 months with tucatinib versus 16.3 months with placebo (hazard ratio 0.64; p<0.0001). That is evidence of delayed progression, not proof of a cure. Overall-survival data are not yet mature, and tucatinib carries a boxed warning for liver toxicity, so eligibility and liver monitoring belong with an oncology team.

Why this approval matters

HER2-positive cancers grow because their cells carry extra HER2 protein, and treatment blocks that signal in several ways. Maintenance therapy aims to extend the control gained from initial treatment, balancing side effects and quality of life. More time before progression matters, even without a cure.

What to know

1. Progression-free survival and overall survival differ. The first tracks time until the cancer worsens; the second, how long patients live, and needs longer follow-up.
2. A hazard ratio of 0.64 means a lower risk of progression or death — not that every patient gained the same benefit.
3. The boxed warning for liver toxicity means blood tests and monitoring are part of treatment, not an optional extra.